过度体脂质对肺移植后死亡率的影响
Ayako Oshima1, Susumu Sato2,3, Yohei Oshima4
1Department of Metabolism and Clinical Nutrition, Kyoto University Hospital, Kyoto, Japan.
JTCVS open
|October 31, 2025
概括
肺移植后一年的高体脂质量指数 (FMI) 与较差的长期存活率有关. 监测身体成分变化对于改善移植后患者预后至关重要.
科学领域:
- 移植医学 移植医学
- 肺部医学 肺部医学
- 身体组成分析 身体成分分析
背景情况:
- 肺移植是末期肺部疾病的拯救生命的手术.
- 肺移植后的长期结果取决于各种因素,包括患者的健康状况.
- 身体组成的变化可能会影响移植后的预后.
研究的目的:
- 研究肺移植后长达两年的身体组成变化与患者长期预后之间的关联.
- 为了确定特定的身体组成指标,预测肺移植后的生存率.
主要方法:
- 对71名肺移植患者 (2013-2018) 的回顾性分析.
- 身体质量指数 (BMI),无脂肪质量指数 (FFMI) 和脂肪质量指数 (FMI) 的评估,移植后的6个月,1年和2年.
- 考克斯的比例危险回归模型用于评估身体组成和死亡率之间的关联.
主要成果:
- 身体质量指数 (BMI),无脂肪质量指数 (FFMI) 和脂肪质量指数 (FMI) 在移植后的一年内显著增加.
- 在移植后的一年,30.3%的患者的FMI高.
- 移植后一年的高FMI是显著降低存活率的独立预测指标 (HR 5.370,P=.014).
结论:
- 肺移植接受者在手术后体验BMI,FFMI和FMI的增加.
- 越来越多的患者在移植后超过FMI的参考值.
- 肺移植后一年内FMI升高与长期预后不佳有关.
更多相关视频
07:37A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes
Published on: October 28, 2021
3.4K
09:54Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
2.2K
相关概念视频
Drug Dosing: Obese Patients
216
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
216
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
233
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
233
Kidney Transplant I: Introduction
321
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
321
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
164
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
164
